• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 11, 2019

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Scientists at the University of Salamanca have demonstrated that free radicals or reactive oxygen species (ROS) produced by astrocytes had a beneficial effect on brain metabolism.  Read More

MIT, Novo Nordisk researchers test ingestible pill to deliver drugs via stomach injection

Large-molecule drugs such as insulin and other proteins require delivery via injection or intravenous infusion. That typically limits their routine use to the most dire circumstances, given the associated inconvenience, expense and pain. To address that, drug delivery guru Robert Langer and other MIT researchers have teamed up with Novo Nordisk A/S to enable the delivery of injectable drugs via an ingestible pill that delivers a shot into the lining of the stomach. Read More

T cells ChAT with blood vessels via neurotransmitter

Researchers have shown that T cells produced the neurotransmitter acetylcholine to affect blood vessel dilation, which helped them control chronic infections. The work was published in the Feb. 8, 2019, issue of Science. Read More

Incarda aiming to develop patient-administered, inhaled AF drug with personal monitor

Developing a new administration route for an existing FDA-approved drug is a classic drug development strategy. That's precisely what Incarda Therapeutics Inc. has long been doing; it's in the midst of a phase II study for Inrhythm, an inhaled flecainide drug-device combo to treat recent-onset paroxysmal atrial fibrillation (PAF). Read More

Earnings

Alnylam Pharmaceuticals Inc., of Cambridge, Mass., reported its global net product revenues for the fourth quarter were $12.1 million for Onpattro (patisiran), to treat hereditary transthyretin-mediated amyloidosis, and $12.5 million for the full year.  Read More

Financings

Pulmatrix Inc., of Lexington, Mass., entered a securities purchase agreement with certain institutional investors, providing for the purchase and sale of about 1.7 million shares of common stock at a price of about $1.46 per share in a registered direct offering priced at the market, resulting in total gross proceeds of about $2.5 million.  Read More

Other news to note

Eli Lilly and Co., of Indianapolis, initiated an exchange offer to divest its remaining interest in Elanco Animal Health Inc., of Greenfield, Ind. Elanco completed its IPO in September 2018, with Lilly retaining an 80.2 percent ownership interest in Elanco. Read More

Regulatory front

The FDA disclosed briefing documents for the meeting Tuesday of the Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee meeting. Panelists from PDAC and DSaRM will take up the matter of the NDA for the esketamine 28-mg single-use nasal spray device, submitted by New Brunswick, N.J.-based Johnson & Johnson company Janssen Pharmaceuticals Inc., as a therapy for treatment-resistant depression.  Read More

Clinical data for Feb. 8, 2019

Read More

Regulatory actions for Feb. 8, 2019

Read More

Hibercell lands $61M series A to target dormant tumor cells

Backed by a $60.75 million series A round, Hibercell Inc. has launched with plans to tackle dormant disseminated tumor cells (DTCs). Read More

Uniqure gene therapy still looking good in hemophilia B at second interim peek

DUBLIN – The mood music coming out of Uniqure NV's phase IIb trial for its hemophilia B gene therapy, AMT-061, remains positive. A second interim readout last week, after an initial peek at the data sparked a share-buying frenzy last November, showed continued improvement in levels of factor IX (FIX) expression in two of the three patients enrolled in the study. The third patient has plateaued but has maintained his response to the therapy, which comprises an adeno-associated virus 5 (AAV5) vector encoding the highly active Padua variant of FIX. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe